Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBT (2016 - 2026)

Organogenesis Holdings has reported EBT over the past 10 years, most recently at $63.4 million for Q4 2025.

  • For Q4 2025, EBT rose 518.62% year-over-year to $63.4 million; the TTM value through Dec 2025 reached $47.0 million, up 1773.32%, while the annual FY2025 figure was $47.0 million, 1773.32% up from the prior year.
  • EBT for Q4 2025 was $63.4 million at Organogenesis Holdings, up from $21.2 million in the prior quarter.
  • Over five years, EBT peaked at $63.4 million in Q4 2025 and troughed at -$25.8 million in Q1 2025.
  • A 5-year average of $6.9 million and a median of $8.2 million in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: soared 670.88% in 2024 and later plummeted 493.67% in 2025.
  • Year by year, EBT stood at $18.9 million in 2021, then crashed by 53.66% to $8.8 million in 2022, then crashed by 120.52% to -$1.8 million in 2023, then soared by 670.88% to $10.3 million in 2024, then surged by 518.62% to $63.4 million in 2025.
  • Business Quant data shows EBT for ORGO at $63.4 million in Q4 2025, $21.2 million in Q3 2025, and -$11.8 million in Q2 2025.